Format

Send to

Choose Destination
  • Showing results for a modified search because your search retrieved no results.
Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):e267-e273. doi: 10.1016/j.clml.2018.04.002. Epub 2018 Apr 14.

Italian Multicenter Study on Accuracy of 18F-FDG PET/CT in Assessing Bone Marrow Involvement in Pediatric Hodgkin Lymphoma.

Author information

1
Positron Emission Tomography Centre, IRMET S.p.A., Affidea, Turin, Italy; PET Pediatric Study Group, Italian Association of Nuclear Medicine and Molecular Imaging, Milan, Italy. Electronic address: angelina.cistaro@affidea.it.
2
Positron Emission Tomography Centre, IRMET S.p.A., Affidea, Turin, Italy.
3
Nuclear Medicine Unit, Umberto I Hospital, Syracuse, Italy.
4
Wolfson Molecular Imaging Centre, University of Manchester, Manchester, United Kingdom.
5
Nuclear Medicine and Molecular Imaging Unit, Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy.
6
Pediatric Onco-Hematology and Stem Cell Transplant Division, City of Health and Science, Regina Margherita Children's Hospital, Turin, Italy.
7
Pediatric Onco-Hematology and Stem Cell Transplant Division, City of Health and Science, Regina Margherita Children's Hospital, Turin, Italy; Italian Association Pediatric Oncology and Hematology, Turin, Italy.
8
Division of Nuclear Medicine, Azienda Ospedaliera Universitaria, Città della Salute e della Scienza, Turin, Italy.
9
Nuclear Medicine Unit, Department of Biomedical Sciences and Morphologic and Functional Images, University of Messina, Messina, Italy.
10
Nuclear Medicine Service, Department of Medicine, University Hospital, Padua, Italy.
11
Department of Child and Woman Health, Oncology Hematology Division, University-Hospital of Padua, Padua, Italy.
12
Maria Letizia Verga Center, MBBM Foundation - San Gerardo Hospital, Monza, Italy.
13
Nuclear Medicine Unit, San Gerardo Hospital, Monza, Italy.
14
Oncoematologia Pediatrica, Azienda Ospedaliera Universitaria, Ospedale Sant'Anna, Ferrara, Italy.
15
Unit of Nuclear Medicine, Department of Diagnostic Imaging, S. Anna University Hospital, Ferrara, Italy.
16
Nuclear Medicine Unit, University of Bologna, Bologna, Italy.
17
Nuclear Medicine Unit, Department of Diagnostic Imaging, E. O. Galliera Hospital, Genoa, Italy.
18
Dipartimento di Ematologia e Oncologia, Pediatrica Istituto G. Gaslini, Genova, Italy.
19
Nuclear Medicine Department and PET/CT Center, ARNAS Garibaldi-Nesima, Catania, Italy.
20
Nuclear Medicine Department, Humanitas Clinical and Research Hospital, Rozzano, Milan, Italy.
21
S. S. Radioterapia Pediatrica e Area Giovani, Istituto di Ricovero e Cura a Carattere Scientifico, Centro di Riferimento Oncologico Aviano, Pordenone, Italy.
22
Nuclear Medicine Unit, University of Bari, Bari, Italy.
23
Pediatric Hematology-Oncology Division, Department of Pediatrics, University of Bari, Bari, Italy.
24
Nuclear Medicine Unit, Istituto di Ricovero e Cura a Carattere Scientifico, National Cancer Institute, Aviano, Italy.

Abstract

INTRODUCTION:

The present study investigated the utility of fluorine-18 (18F) fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in assessing bone marrow involvement (BMI) compared with bone marrow biopsy (BMB) in newly diagnosed pediatric Hodgkin lymphoma (HL).

PATIENTS AND METHODS:

A total of 224 pediatric patients with HL underwent 18F-FDG PET/CT at staging. BMB or follow-up imaging was used as the standard of reference for the evaluation of BMI.

RESULTS:

18F-FDG PET/CT was negative for BMI in 193 cases. Of the 193 patients, the findings for 16 were originally reported as doubtful and later interpreted as negative for BMI, with negative findings on follow-up imaging and BMB. At BMB, 1 of the 16 patients (6.25%) had BMI. Of the 193 patients, 192 (99.48%) had negative BMB findings. Thus, the 18F-FDG PET/CT findings were truly negative for 192 patients and falsely negative for 1 patient for BMI.

CONCLUSION:

18F-FDG PET/CT showed high diagnostic performance in the evaluation of BMI in pediatric HL. Thus, BMB should be ideally reserved for patients presenting with doubtful 18F-FDG PET/CT findings for BMI.

KEYWORDS:

BMI; Bone marrow biopsy; Computed tomography; Newly diagnosed pediatric HL; Positron emission tomography

PMID:
29739722
DOI:
10.1016/j.clml.2018.04.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center